Introduction:

 Liquid biopsy market accounted for US$ 1.32 billion in 2020 and is estimated to be US$ 7.92 billion by 2030 and is anticipated to register a CAGR of 19.8%.

Liquid biopsy is a non-invasive alternative to surgical biopsies, which enables healthcare practitioners to collect information regarding tumor through a simple blood sample. A liquid biopsy test can detect epidermal growth factor receptor (EGFR) gene mutations, which occur in patients suffering from non-small cell lung cancer. Liquid biopsy traces tumor DNA in the blood sample, which can aid in selecting treatment for a particular patient. These biopsies are majorly conducted for identification of lung, breast, and prostate cancer.

The world is one of the major factors driving growth of the liquid biopsy market, as liquid biopsies are non-invasive and require only 5 milliliters of blood for performing detection test. Furthermore, liquid biopsy offer advantages such as tolerability and convenience to detect disease progression or treatment resistance before clinical symptoms appear. Liquid biopsies detect genetic changes more effectively as compared to conventional tissue biopsy.  Moreover, the test also detects risks of developing chromosomal abnormalities such as Edwards’s syndrome, Down syndrome, and X and Y chromosome abnormalities, which in turn is fueling market growth. However, variability of results interpretation due to sensitivity of biopsy may restrain growth of the market.

Generally, there has be increase in the population number of people who have cancer disease. Cancer is the second leading death causes in world. Liquid biopsy have many benefits of cancer daignostics process that are – therapy monitoring, patient comfort, and tumor heterogeneity. the sevral factors that attributed to cancer such as infectious agents ( Hepatitis B and C) , tobacco consumption and environmental factors .

The liquid Biopsy market is segmented based on product, sample, application, end user and region.

On the basis of sample, the liquid biopsy market is segmented into Cell free DNA, Circulating Tumor cell and Exosomes. Based on products the target market is segmented into Reagents & kits and Equipment’s. On the basis of application, the target market is segmented into oncology testing, Non-invasive prenatal testing and Transplant care. On the basis of end user the target market is segmented into hospitals, Research laboratories, diagnostic Laboratories and patients. On the basis of region, the market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa.

Regional Insights:                                            

The liquid biopsy market accounted for US$ 1.32 billion in 2020 and is estimated to be US$ 7.92 billion by 2030 and is anticipated to register a CAGR of 19.8%. On region the liquid biopsy market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to lead the market and estimate for about 35% revenue share in 2020. As North America is the leading liquid market and have highly well-developed system such as healthcare in US and Canada.

Report Scope:

Attribute	Details
Base year for estimation	2020
Forecast period	2020 – 2030
Market representation	Revenue in USD Million & CAGR from 2020 – 2030
Market Segmentation	By Product- Reagents & Kits and Equipment By Sample– Cell Free DNA, Circulating Tumor Cells, and Exosomes By Application– Oncology Testing, Non-Invasive Prenatal Testing, and Transplant Care By End User - Hospitals, Research Laboratories, Diagnostic Laboratories, and Patients
Regional scope	North America - U.S., Canada Europe - UK, Germany, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Rest of Asia-Pacific Latin America - Brazil, Mexico, Rest of Latin America Middle East & Africa – GCC, South Africa, UAE, Rest of Middle East .
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the liquid biopsy market report based on product, sample, End User, application, and region.

 

                          

Liquid Biopsy Market, By Region:

• North America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • U.S.
  • Canada

Key players operating in the liquid biopsy market include Illumina, Inc., Roche AG, Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc., CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA.

•  Illumina
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Roche AG, Natera, Inc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Laboratory Corporation of America Holdings (LabCorp)
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Qiagen N.V
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
•  Thermo Fisher Scientific Inc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Exact Sciences Corp
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
•  Biocept, Inc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Genomic Health Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
•  Guardant Health
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• TrovaGene Inc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• CareDx Inc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Adaptive Biotechnologies Corporation
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Biocartis SA.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
   • PORTER’s
   • Investment Outlook
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for Liquid Biopsy Strategies
     • Key Questions this Study will Answer
     •  
       • By Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus, and others)
       • By Region (North America, Europe, Asia Pacific, Middle East, Latin America, and Africa) 
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Overview
   • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
   • Y-o-Y Growth Analysis (%), 2020 – 2030
   • Regional Trends
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Regional Analysis
   • Regional Revenue Analysis
   • Regional By segment Analysis
   • Reasons for regional growth
   • Key Player of particular region
   • Countries Include in the report:
     • North America (U.S., Canada)
     • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
     • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
     • Latin America (Brazil, Mexico, Rest of Latin America)
     • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
   • Competitive Overview
   • Competitive Benchmarking
   • Market Share Analysis
   • Key Developments In The Liquid Biopsy Market
   • Key Developments: Mergers & Acquisitions
   • Key Developments: Collaboration
   • Key Developments: Contracts & Agreements
   • Key Developments: Expansion
   • Key Developments: Product Developments
2. Company Profiles

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies
• SWOT Analysis
• Illumina, Inc., Roche AG, Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc., CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA.

1. The Last Word
   • Future Impact
   • About Us
   • Contact